RELMADA THERAPEUTICS, INC.
Recent Filings
All 581 filings →| Form | Description | Date |
|---|---|---|
| 8-K | CURRENT REPORT | Mar 20, 2026 |
| 10-K | ANNUAL REPORT | Mar 19, 2026 |
| 8-K | CURRENT REPORT | Mar 9, 2026 |
| SCHEDULE 13G/A | — | Feb 17, 2026 |
| SCHEDULE 13G | — | Feb 17, 2026 |
| SCHEDULE 13G | — | Feb 12, 2026 |
| 424B5 | PROSPECTUS SUPPLEMENT | Jan 30, 2026 |
| 4 | — | Dec 16, 2025 |
| 4 | — | Dec 16, 2025 |
| 4 | — | Dec 16, 2025 |
Insider Transactions
View all →| Insider | Title | Type | Shares | Owns After | Date |
|---|---|---|---|---|---|
| TRAVERSA SERGIO | Chief Executive Officer | Purchase | 27,500 @ $4.12 | 1,300,000 | Dec 15, 2025 |
| Shenouda Maged | Chief Financial Officer | Purchase | 11,665 @ $4.12 | 800,000 | Dec 15, 2025 |
| Ence Chuck | CAO and COO | Purchase | 136,000 @ $2.20 | 403,931 | Nov 5, 2025 |
| TRAVERSA SERGIO | Chief Executive Officer | Purchase | 272,500 @ $2.20 | 1,272,500 | Nov 5, 2025 |
| Shenouda Maged | Chief Financial Officer | Purchase | 500,000 @ $2.20 | 788,335 | Nov 5, 2025 |
| Kelly Paul Edward | Chief Operating Officer | Purchase | 90,000 @ $2.20 | 502,295 | Nov 5, 2025 |
| TRAVERSA SERGIO | Chief Executive Officer | Purchase | 129,455 @ $0.67 | 944,024 | Aug 26, 2025 |
| TRAVERSA SERGIO | Chief Executive Officer | Purchase | 172,314 @ $0.45 | 556,338 | May 19, 2025 |
| Kelly Paul Edward | Chief Operating Officer | Purchase | 200,000 @ $0.43 | 412,295 | May 16, 2025 |
| Shenouda Maged | Chief Financial Officer | Purchase | 60,000 @ $0.52 | 288,335 | May 16, 2025 |